Observational studyCardiovascular and interventional radiology2026
Embolisation of Type 2 Endoleaks Associated with Sac Expansion-Outcomes from a Single-Centre Cohort.
Observational study in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the outcomes of a patient cohort following transcatheter embolisation for type 2 endoleaks associated with sac expansion. MATERIALS AND
methodsA retrospective single-centre observational study was performed between September 2005 and June 2023. Technical success rates and long-term outcomes were evaluated including technical factors associated with endoleak recurrence and rupture. One hundred transcatheter embolisations were performed for type 2 endoleaks in 72 patients (64 male and 8 female).
resultsTechnical success (cessation of flow in the endoleak on angiography) was achieved in 77/100 (77%) procedures. Clinical success (freedom from sac growth on surveillance) was achieved in 82% at 12 months, 70% at 24 months and 59% at 60 months. Persistent endoleaks were found in 27%, with 7% developing a new type 2 and 14% developing new type 1, 3 or 5 endoleaks. The rupture rate was 7%, including 2/7 persistent type 2 endoleaks, 4/7 new type 1 or 3 endoleaks and 1/7 type 5 endoleak. Embolisation was performed either via a transarterial route (74%) or via direct sac puncture (24%), the latter demonstrating a significant correlation with technical success (p=0.018).
conclusionsThis study confirms the importance of embolisation as the main treatment modality of type 2 endoleaks with freedom from sac growth achieved in 70% of patients at 24 months. However, this remains a complex entity with persistent sac growth, risking the development of type 1 or 3 endoleaks, which carry a risk of late sac rupture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.